Non-metastatic castration resistant prostate cancer
DOI: https://doi.org/10.22591/magyurol.2023.2.rieszp.96
Authors:
Riesz Péter dr., Szűcs Miklós dr., Szalontai János dr., Horváth András dr.
Semmelweis Egyetem, Urológiai Klinika és Andrológiai Centrum, Budapest (igazgató: Nyirády Péter dr.)
Summary
Prostate cancer is the most common urological malignancy. In this review, the authors discuss the definition, epidemiological data, diagnostics and treatment options of non-metastatic castration resistant prostate cancer. One-third of patients with nmCRPC develop metastases within two years. Only 2-8% of patients belong to this group, but its significance is due to the fact that effective medication have been developed for the treatment of high-risk patients in recent years. Since 2018, it has been possible to increase the metastasis-free time, the symptom-free time and the overall survival time with three drugs. Therefore, the most important task of oncologists and urologists is to detect among the patients under their treatment those non-metastatic castration-resistant cases who have a high risk of developing bone metastases, because they have the opportunity to ensure longer symptom-free and complete survival.